The prognostic significance of biochemical markers of bone metabolism in patients with bone metastases from solid tumors other than breast and prostate cancer

被引：0
|
作者：
Brown, JE
Cook, RJ
Major, P
Lipton, A
Lee, KA
Zheng, M
Hei, YJ
Coleman, RE
机构：
[1] Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England
[2] Univ Waterloo, Waterloo, ON N2L 3G1, Canada
[3] Hamilton Reg Canc Ctr, Hamilton, ON L8V 1C3, Canada
[4] Milton S Hershey Med Ctr, Hershey, PA USA
[5] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1596 / 1596
页数：1
相关论文
共 50 条
  • [41] Clinical features and prognostic factors for patients with bone metastases from prostate cancer
    He, Jian
    Zeng, Zhao-Chong
    Yang, Ping
    Chen, Bing
    Jiang, We
    Du, Shi-Suo
    ASIAN JOURNAL OF ANDROLOGY, 2012, 14 (03) : 505 - 508
  • [42] Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications
    Eric C. Nelson
    Christopher P. Evans
    Chong-Xian Pan
    Primo N. Lara
    World Journal of Urology, 2007, 25 : 393 - 399
  • [43] Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications
    Nelson, Eric C.
    Evans, Christopher P.
    Pan, Chong-Xian
    Lara, Primo N., Jr.
    WORLD JOURNAL OF UROLOGY, 2007, 25 (04) : 393 - 399
  • [44] Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer
    Wang, Ruliang
    Zhang, Shaohua
    Jiang, Zefei
    Tian, Jizheng
    Wang, Tao
    Song, Santai
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2017, 44 (01): : 88 - 93
  • [45] Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?
    Bombardieri, E
    Martinetti, A
    Miceli, R
    Mariani, L
    Castellani, MR
    Seregni, E
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1997, 24 (11) : 1349 - 1355
  • [46] Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?
    Emilio Bombardieri
    Antonia Martinetti
    Rosalba Miceli
    Luigi Mariani
    Maria Rita Castellani
    Ettore Seregni
    European Journal of Nuclear Medicine, 1997, 24 : 1349 - 1355
  • [47] Zoledronic acid has broad long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer, prostate cancer, and other solid tumors
    Coleman, R
    Rosen, L
    Gleason, DM
    Zheng, M
    BONE, 2004, 34 : S84 - S85
  • [48] Bone remodeling markers in the detection of bone metastases in breast cancer
    De la Piedra, C
    Ruibal, A
    García-Moreno, C
    Lefort, M
    Quiroga, I
    Rubert, M
    EUROMEDLAB 2003: PROCEEDINGS OF THE 15TH IFCC-FESCC EUROPEAN CONGRESS OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, : 311 - 314
  • [49] Biochemical evaluation of bone turnover and bone collagen degradation in a large series of patients with bone metastases from breast cancer
    Dumon, JC
    Siwek, B
    Kheddoumi, N
    Journé, F
    Mancini, I
    Cstoth, I
    Body, JJ
    BONE, 2001, 28 (05) : S138 - S139
  • [50] BIOCHEMICAL MARKERS OF BONE TURNOVER IN PATIENTS WITH OSTEOLYSIS FROM BREAST-CANCER
    MONTI, M
    SCAZZOSO, A
    BEVILACQUA, M
    CALZAFERRI, G
    LOCATELLI, E
    CATANIA, S
    GANDINI, R
    CUNIETTI, E
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1990, 9 (03) : 145 - 150
12345